Drugs / CCT301-59
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03960060 | May 2019 → Jun 2022 | gastric cancer, malignant pancreatic neoplasm, soft tissue sarcoma, urinary bladder cancer | Shanghai PerHum Therapeutics Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03393936 | Mar 2018 → Jun 2022 | renal cell carcinoma | Shanghai PerHum Therapeutics Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CCT301-59 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03393936 ↗ |
| Modality | Cell therapy | “CAR modified autologous T cells (CCT301-59)” NCT03960060 ↗ |
| Route | Intravenous | “by intravenous (IV) injection” NCT03393936 ↗ |